Skip to main content

Table 2 HIV-1 and HIV-2 amino acid polymorphisms at positions associated with INI (RAL and EGV) resistance

From: HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients

Mutation categories

Known amino acid substitution

Rate of INI resistance mutations in INI-naïve patients (%)

HIV-1 amino acid substitution

HIV-2 clade A ROD subtype consensus

HIV-2 substitution (4 strains)

   

HAART-naïve (n = 41)

RTI/PI-experienced (n = 54)

  

Primary

E92Q

   

E

 

mutations

F121Y

   

F

 
 

E138A

   

S

T3

 

G140A/S

   

G

 
 

Y143R7C/H

   

Y

 
 

S147G

   

S

 
 

Q148H/R/K

   

Q

 
 

S153Y

 

A 1

 

A

 
 

N155H

   

N

 
 

R263K

   

R

 

Secondary mutations

H51Y

   

H

 
 

T66I

   

T

 
 

L74A/M/I

7 (7.4)

I2/M1

I4

I

 
 

Q95K

  

R 1

R

 
 

T97A

2 (2.1)

S 1

A2

T

 
 

E138K

  

D 1

S

T3

 

Q146P

   

N

 
 

V151I

   

V

 
 

E157Q

3 (3.2)

Q2

Q1

H

 
 

G163R

  

E 2 /N 1 /A 1

S

G2

 

I203M

3 (3.2)

M2

M1

M

 
 

S230R/M

 

N 4

N 2

G

 

Polymorphic and non-polymorphic mutations

V72I

50 (52.6)

I22

I28/D 1

I

V2

 

T125K

 

A 19 /M 1 /V 1

A 24 /V 4 /P 1

E

D2

 

A128T

   

M

 
 

K160D

 

Q 1 /R 1

Q 1

N

 
 

V165I

18 (18.9)

I8

I10

I

 
 

V201I

68 (71.6)

I30

I38

I

 
  1. RTI: reverse trancriptase inhibitor; PI: protease inhibitor; INI: integrase inhibitor.
  2. New polymorphisms are reported in boldface.